Bionxt Solutions Inc. Stock
Price
Target price
€0.28
€0.28
-5.800%
-0.016
-5.800%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Bionxt Solutions Inc. Stock
Bionxt Solutions Inc. took a tumble today and lost -€0.016 (-5.800%).
So far the community has only identified positive things for Bionxt Solutions Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Bionxt Solutions Inc. in the next few years
Pros
?
S********** s********
?
B****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
News
BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps
VANCOUVER, BC / ACCESSWIRE / March 18, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that based on the recent success of its
BioNxt Reports Successful Results From ODF Cladribine PK Study
VANCOUVER, BC / ACCESSWIRE / March 13, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that the comparative pharmacokinetic
BioNxt Reports Completion of ODF Cladribine PK Study
VANCOUVER, BC / ACCESSWIRE / March 4, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that the comparative pharmacokinetic